Introduction
Understanding cellular immunity to HIV-1 is crucial in the design and evaluation of HIV immunotherapies. Such background data have almost exclusively been obtained through in vitro studies on T lymphocytes derived from peripheral blood mononuclear cells (PBMC) [1] . These include the prevalence of HIV-specific T cells, their dysfunctional activation, proliferation, skewed maturation as well as viral escape [1] [2] [3] [4] [5] . In contrast, solid clinical data are lacking on how HIV-specific T-cell responses in human tissues, including lymphoid organs, compare to responses exerted by T cells in peripheral blood. Because less than 2% of the lymphocytes reside in blood, T cells in PBMC may not necessarily reflect the specificities or functions of the tissue T-cell counterparts in all situations [1, 6] .
Most HIV immunotherapy trials will ultimately examine virological control in the absence of highly active antiretroviral treatment (HAART) and rely on informative correlates of HIV-specific immune responses. However, in this situation, specific responses in PBMC might differ from T-cell responses in the tissues during onset of viraemia: Mice chronically infected with lymphocytic choriomeningitis virus develop a numerical excess of functional, specific T-cell clones in tissues compared to low numbers of functionally 'exhausted' T-cell clones in PBMC [7] . In keeping with this notion, we present the first clinical data showing decreasing T-cell responsiveness to HIV p24 antigens in PBMC during recurrence of HIV viraemia, whereas a corresponding in vivo correlate of cellular immune responses, namely classical delayed type hypersensitivity (DTH) skin testing, tended to increase.
Methods
Vacc-4x is composed of four water-soluble peptides (24-27 amino acids in length), based on consensus sequences within the HIV-1 core protein p24. The Vacc-4x-peptides were modified according to an inhouse bioinformatics model to enhance HLA binding and presentation and thereby improve cellular immune responses to their native peptide counterparts [8] .
A clinical phase IIa dose-finding and extended safety trial with the peptide-based immunotherapy candidate Vacc-4x was conducted with informed patient consent and approvals from the Regional Ethics Committee and Norwegian Medicines Agency. Forty healthy HIV-infected patients on long-term, effective HAART, having 550 Â 10 6 cells/l CD4 T cells and HIV RNA < 50 copies/ml (medians) were initially randomized into two dosage arms. Only 38 patients are included in this study, because one patient dropped out after the first vaccination and another later left the study due to severe coronary heart disease. Vacc-4x targeted Langerhans' dendritic cells through intradermal injection of low dose recombinant granulocyte macrophage-colony stimulating factor (GM-CSF) as local adjuvant [9] . HIV RNA was monitored by the COBAS Amplicor HIV-1 monitor test (Roche, Branchburg, New Jersey, USA).
DTH to Vacc-4x was obtained by intradermal injection of 0.4 mg peptides in 0.1 ml H 2 O without previous injection of GM-CSF. Sterile water was initially included as negative control at baseline [9] . The perpendicular diameters of palpable skin infiltrates were used to calculate the circular areas 48 h after injection.
Formalin-fixed, paraffin-embedded skin biopsy tissue slides from a typical DTH infiltrate were stained for the proliferation marker Ki67 (clone MIB-1, DAKO, Denmark) using the DAB detection kit (Ventana Systems, Tucson, Texas, USA), boiled in citrate buffer (10 min), and then stained with a polyclonal antibody to CD3 (NovoCastra, Newcastle, UK) with alkaline phosphatase red detection kit (Ventana Systems).
T-cell proliferative responses were measured in freshly isolated PBMC pulsed with the fluorescent cytosol stain CFSE at 4 mM for 5 min and subsequently stimulated with Vacc-4x peptides (2.5 mg/ml), recombinant p24 (2 mg/ml) and cytomegalovirus (CMV) lysate for 7 days, as detailed elsewhere [9] . Freshly thawed antigen preparations were used, which had been dispersed and frozen in small volumes pre-study.
All data are presented as median values (25-75 percentile range) unless stated otherwise. Two-tailed Wilcoxon matched pairs tests were used for paired comparisons.
Results
We have recently reported data from a phase IIa dose-finding trial of a HIV p24 peptide-based vaccine (Vacc-4x) which was given in 10 doses over 26 weeks to HIV-infected patients taking HAART. New Vacc-4x-specific responses were detected in 90% of the patients with development of both DTH responses and CD8 and CD4 T-cell proliferative responses in PBMC [9] . As an extension of this study and with informed consent and formal approvals, a 4-week structured treatment interruption (STI) was introduced in order to exclude viraemia-associated adverse events related to Vacc-4x, and to simultaneously boost HIV-specific immunity with recurrent, autologous HIV. After 8 more weeks on HAART, a final 14-week STI was initiated, from week 38 to end-of-study at week 52. This period should be sufficient for stabilizing HIV RNA levels [10] , which increased from 100 (< 50-400) to 72 500 (28 000-170 000) copies/ml, respectively. Before and at the end of this STI, i.e., at weeks 38 and 52, T-cell responsiveness to Vacc-4x peptides was monitored in the 38 eligible patients both in vivo by DTH responses, and in vitro by T-cell proliferation assay. The latter assay was chosen because immune control of HIV replication has mainly been attributed to proliferative, HIV-specific T-cell responses [11] . The other major data from this dose-finding study have been presented elsewhere ( [12] , A.-M. B. Kran et al., unpublished data).
During recurrence of viraemia from week 38 to week 52, both Vacc-4x p24 peptide-and p24 protein-specific T-cell proliferation in stimulated PBMC in vitro decreased by 81% and 93%, respectively (medians, P 0.03). This was interpreted as a direct consequence of recurrent HIV viraemia, because the proliferative T-cell responses to non-HIV antigens (i.e., CMV) remained intact (Fig. 1a) . Based on these PBMC data alone one could have concluded that a substantial proportion of Vacc-4x reactivity in vivo had been lost due to recurrence of replicating HIV. In contrast, the ability to recruit and activate T cells in vivo, as reflected by DTH induration areas, were stable or rather tended to expand by 36% during viraemia (P ¼ 0.08), and significantly did so in patients having DTH at week 38 below the median DTH for the whole cohort (P ¼ 0.04) (Fig. 1b) . This difference was probably not caused by time-dependent assay variations, because patients who were tested on the same day were usually at different study time points, due to a inclusion period of about 6 months. The recruitment and proliferation of specific T cells in DTH were confirmed by immunohistochemical analysis of skin biopsy (Fig. 2) .
Discussion
STI have been partially successful by inducing improved, immune-mediated viral control [13] . However, rapid decrease in functional HIV-specific T cells in PBMC during viraemia, as observed in this study and in others [14] , has created concern. Moreover, this phenomenon might provide data that are interpreted as discouraging in immunotherapy trials. For example, a recent clinical trial [15] sought to determine whether improved viral control could be achieved in chronically infected HIV patients following four consecutive, 2-week STI. This was examined with a final 12-week STI, comparable to our study. It was found that the responding patients, i.e., those having lowest HIV RNA levels, actually had significantly lower numbers of HIV-specific CD8 T cells in PBMC [15] . This could call into question the informative value of the assays used, given the fact that specific CD8 T cells are considered essential for controlling HIV replication [1, 5, 13] .
DTH have been widely used to estimate T-cell responses in vivo to a number of pathogens but have been poorly explored using HIV antigens. DTH responses in this study were used to monitor the presence and longevity of T-cell responses to Vacc-4x peptide antigens as a practical in vivo assay that could be directly compared with PBMC responses. The validity of this DTH assay was supported by several factors: A relation between reactivity to Vacc-4x p24 peptides and HIV-specific immunity was observed by their covariance with the p24 whole protein responses. We have already shown that the Vacc-4x DTH infiltrates were mediated by specific T cells; most patients had negative DTH before immunization, and it was found typical dominance of T cells in DTH biopsy [9] . We now found immunohistochemically that the Vacc-4x DTH infiltrates also contained Ki-67 positive T cells, indicating that these peptide-specific T cells were indeed able to proliferate also in vivo. Moreover, we recently observed that DTH high-responders ultimately achieved significantly lower HIV RNA levels at week 52 without any other differences in immunological or virological parameters, either pre-HAART or pre-study ( [12] , A.-M. B. Kran et al., unpublished data). This might suggest that HIV-specific responses in the tissues are better preserved than indicated by the decreasing PBMC responses in vitro.
In conclusion, onset of HIV-1 viraemia induced a substantial discrepancy between preserved HIV-specific immune responses in vivo and decreased T-cell responsiveness in PBMC in vitro. Most immunotherapy trials will monitor immune responses in HAART-free periods and hence depend on informative assays. These results question whether antigen-stimulated PBMC, as the only surrogate marker for HIV-related immune responses during viraemia, accurately reflect HIV-related immune responses in vivo in all situations. Thus, in future clinical immunotherapy trials, the informative value of PBMC responses should be compared with other assay modalities, such as DTH. 
